Navigation Links
Uroplasty Reports Third Quarter Fiscal 2009 Results
Date:2/3/2009

MINNEAPOLIS, Feb. 3 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the third quarter of fiscal 2009 ended December 31, 2008. Net sales for the third quarter of fiscal 2009 were $3.4 million versus $3.7 million during last fiscal year's third quarter.

"As we discussed in conjunction with the release of our fiscal second quarter results, our Urgent PC system to treat overactive bladder syndrome has been facing a challenging market environment created by insurance reimbursement uncertainties," said David Kaysen, President and CEO. "While a growing number of physicians are recognizing the benefits of Urgent PC, and the treatment continues to receive reimbursement from many insurance plans, our market momentum has slowed due to the uncertainty with insurance reimbursement.

"A major part of our strategy to expand and support third-party reimbursement coverage of Urgent PC treatment is the SUmiT study, which we announced in October. The study is designed to directly compare the effectiveness of Urgent PC treatment to non-active treatment and the enrollment of 221 patients was completed two months ahead of schedule," added Mr. Kaysen. The SUmiT study is evaluating reductions in urinary urgency, urge incontinence and frequency of urinary voids, as well as patient quality of life measures. This study, now expected to be completed by late summer of 2009, is taking place at 23 urology and urogynecology centers across the United States.

"Meanwhile, U.S. sales of Macroplastique are building momentum," added Mr. Kaysen. "Through our expanded sales focus and training, we are capitalizing on recent market concerns regarding competitive pro
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Uroplasty to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York
2. Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007
3. Uroplasty to Host Third Quarter Conference Call on February 11
4. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
5. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
6. Recent Reports Regarding Mercury and High Fructose Corn Syrup Flawed and Misleading
7. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
8. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
9. CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009
10. Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results
11. Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... D.C., September 30, 2014 Applying a well-known ... researchers at Harvard University has demonstrated the ability ... -- work that holds promise for making future, ... detailing the sides of next-gen rocket ships and ... light passes through oil in water, it becomes ...
(Date:9/30/2014)... Shimadzu Scientific Instruments has released the DSES-1000 long-travel ... for measuring displacement in rubber and other soft ... distance, the DSES-1000 can measure elongations up to ... mm. In addition, it achieves +/- 0.2 percent ... +/- 100 µm below 50-mm stroke. , The ...
(Date:9/30/2014)... , Sept. 30, 2014  RegeneRx Biopharmaceuticals, Inc. ... that it has received a Canadian Patent for ... Peptides.  This patent includes claims using thymosin beta ... actin-sequestering peptides for these purposes.  The patent will ... Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
(Date:9/30/2014)... 2014  KemPharm, Inc., a clinical-stage specialty pharmaceutical ... proprietary new molecular entity (NME) prodrugs, announced today ... (USPTO) issued U.S. Patent No. 8,816,083 to KemPharm ... Acid Derivatives and Heteroaryl Carboxylic Acid Conjugates of ... The patent, which extends through 2032, ...
Breaking Biology Technology:Taking thin films to the extreme 2Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2
... April 23 MedQuist Inc. (Nasdaq: ... services, today announces that it has completed the purchase ... Inc., MedQuist,s majority owner, has acquired the stock of ... the combined companies will offer unprecedented opportunities for healthcare ...
... April 23 Moffitt Cancer Center announces steadily growing ... chemotherapy for Non Small Lung Cancer patients.  Each year, more than ... , , ... in cells to predict response to cisplatin-based chemotherapy.   The correlation ...
... April 22 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc. ("Dragon Pharma" ... a complaint regarding its proposed merger with Datong Investment Inc ... Circuit for Palm Beach County , State of ... Yanlin Han , a director and Chief Executive Officer ...
Cached Biology Technology:MedQuist Announces Completion of Spheris Transaction 2MedQuist Announces Completion of Spheris Transaction 3Moffitt Cancer Center Announces Growing Interest in Recently Launched Prognostic Test for Non-Small Cell Lung Cancer 2Moffitt Cancer Center Announces Growing Interest in Recently Launched Prognostic Test for Non-Small Cell Lung Cancer 3Moffitt Cancer Center Announces Growing Interest in Recently Launched Prognostic Test for Non-Small Cell Lung Cancer 4Complaint Filed Regarding Proposed Merger 2Complaint Filed Regarding Proposed Merger 3Complaint Filed Regarding Proposed Merger 4
(Date:9/30/2014)... Evidence of the environmental effects of moorland burning is ... the subject, with the aim of relieving tensions on ... , The EMBER (Effects of Moorland Burning on the ... burning on moorland, which is practised predominantly to support ... impacts on peat hydrology, peat chemistry and physical properties, ...
(Date:9/30/2014)... captured the popular attention of both children and aquarium ... sold as dehydrated eggs, these tiny brine shrimp readily ... tank of salt water. , Physicists, though, are ... shrimp vertically migrate in large groups in response to ... night and retreating deeper during the day. , Two ...
(Date:9/30/2014)... New England Journal of Medicine reports positive ... drug crizotinib against the subset of lung cancer marked ... study of 50 patients with advanced non-small cell lung ... rate was 72 percent, with 3 complete responses and ... it takes for the disease to resume its growth ...
Breaking Biology News(10 mins):Grouse moor burning causes widespread environmental changes 2Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2
... ARBOR, Mich.---A new study of expectant mothers suggests that ... are present in many industrial and consumer products including ... alarming rise in premature births. Researchers at ... that women who deliver prematurely have, on average, up ...
... for a lazy partner by working harder to bring up their ... of parenting, says research by bird biologists at the University of ... to be involved in raising young, but it is very common ... to find out why, for some animals, parents stick together. ...
... is being officially opened today (3 July) by Nobel ... the Lord-Lieutenant of Norfolk. The Genome Analysis Centre ... the science of understanding the genetic makeup of organisms ... knowledge can then be used for developments that include ...
Cached Biology News:Chemicals in common consumer products may play a role in pre-term births 2Battle of the sexes benefits offspring, says research 2New national genome center launched 2New national genome center launched 3
These 96-well 0.2 ml thin-wall PCR plate caps are caps that are used to seal 96-well, 0.2 ml thin-wall PCR plates. Supplied as 300 caps....
... sequence analysis software with the DeCypher Engine accelerator ... you can perform searches like these from your ... database in under 6 days Align ... Use HMM analysis to compare 100,000 sequences ...
Mouse monoclonal antibody to FMN2 - formin 2...
Rabbit polyclonal to SMARCA2 / BRM - ChIP Grade ( Abpromise for all tested applications). entrezGeneID: 6595 SwissProtID: P51531...
Biology Products: